Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on April 28, 2016, to announce its first-quarter 2016 financial results. The report primarily serves to furnish a press release detailing these results, along with supplemental information available on the company's website. Investors should refer to the furnished press release (Exhibit 99.1) and supplemental materials (Exhibit 99.2) for specific financial performance data, including revenue, earnings, and any forward-looking guidance provided for the quarter.
Key Highlights
- 1BMY announced its first-quarter 2016 financial results via a press release.
- 2The 8-K filing includes the press release as Exhibit 99.1.
- 3Supplemental financial information is also provided as Exhibit 99.2 and accessible on the company's website.
- 4Investors should consult the furnished documents for detailed financial performance metrics.
- 5The filing date indicates that the results announced are for the quarter ending approximately March 31, 2016.
- 6This report does not contain new operational or strategic developments beyond the financial results announcement.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially report Bristol-Myers Squibb's financial results for the first quarter of 2016, as announced in their press release.
Detailed financial results for Q1 2016 can be found in the press release (Exhibit 99.1) and supplemental information (Exhibit 99.2) furnished with this 8-K filing, and also available on the company's website (www.bms.com).
No, this 8-K filing is primarily focused on the disclosure of financial results for the first quarter of 2016. It does not appear to contain new strategic announcements or significant business updates beyond the financial performance.